Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Hold” by Brokerages

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) has earned an average rating of “Hold” from the twelve analysts that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $13.13.

Several research firms have weighed in on YMAB. Morgan Stanley lowered Y-mAbs Therapeutics from an “equal weight” rating to an “underweight” rating and set a $4.00 target price on the stock. in a report on Friday, January 27th. Wedbush upgraded Y-mAbs Therapeutics from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $5.00 to $13.00 in a report on Wednesday, May 10th. Guggenheim lowered Y-mAbs Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, April 3rd. Canaccord Genuity Group cut their price target on Y-mAbs Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, March 31st. Finally, HC Wainwright cut their price target on Y-mAbs Therapeutics from $19.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, April 4th.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, Director Johan Wedell-Wedellsborg purchased 101,740 shares of the stock in a transaction on Monday, May 15th. The shares were purchased at an average price of $9.65 per share, with a total value of $981,791.00. Following the completion of the transaction, the director now directly owns 4,280,205 shares in the company, valued at $41,303,978.25. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 20.61% of the stock is owned by company insiders.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Institutional investors have recently bought and sold shares of the business. Denali Advisors LLC bought a new stake in shares of Y-mAbs Therapeutics in the first quarter valued at approximately $42,000. Alpine Global Management LLC bought a new stake in shares of Y-mAbs Therapeutics in the fourth quarter valued at approximately $116,000. GSA Capital Partners LLP bought a new stake in shares of Y-mAbs Therapeutics in the fourth quarter valued at approximately $484,000. HRT Financial LP bought a new stake in Y-mAbs Therapeutics during the fourth quarter worth $323,000. Finally, Cornercap Investment Counsel Inc. bought a new stake in Y-mAbs Therapeutics during the fourth quarter worth $235,000. Institutional investors and hedge funds own 53.96% of the company’s stock.

Y-mAbs Therapeutics Stock Down 6.1 %

NASDAQ:YMAB opened at $9.71 on Friday. Y-mAbs Therapeutics has a 12-month low of $2.70 and a 12-month high of $20.48. The firm has a market capitalization of $424.11 million, a P/E ratio of -5.75 and a beta of 0.78. The stock’s fifty day simple moving average is $5.89 and its 200-day simple moving average is $4.90.

Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating) last posted its quarterly earnings results on Monday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.16. The business had revenue of $20.30 million for the quarter, compared to analyst estimates of $15.55 million. Y-mAbs Therapeutics had a negative return on equity of 64.77% and a negative net margin of 98.48%. The firm’s revenue was up 93.3% on a year-over-year basis. During the same period last year, the company earned ($0.64) EPS. As a group, equities research analysts expect that Y-mAbs Therapeutics will post -0.96 earnings per share for the current year.

Y-mAbs Therapeutics Company Profile

(Get Rating)

Y-mAbs Therapeutics, Inc is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.